Citations

Clear

350 citation(s) found for "Stevens, V".

Activation of cardiorenal and pulmonary tissue endothelin-1 in experimental heart failure
Luchner, Andreas, Jougasaki, Michihisa , Friedrich, Erik B., Borgeson, Daniel D., Stevens, Tracy L., Redfield, Margaret M. , Riegger, Günter A.J., Burnett, John C.

Mayo Clinic

American Journal of Physiology-Regulatory, Integrative and Comparative Physiology | December 25, 2017 | Volume: 279 | Issue: 3 | Pages: R974-R979

10.1152/ajpregu.2000.279.3.r974 | PMID 10956256 Get It

Endothelin-1 (ET-1) is a peptide that has been implicated in congestive heart failure (CHF). Although increased concentrations of circulating ET-1 have been repeatedly demonstrated, the activation of local ET-1 in target tissues of CHF remains poorly defined. Our objective was to characterize ET-1 tissue concentrations and gene expression of prepro ET-1 in myocardial, renal, and pulmonary tissue in rapid ventricular pacing-induced canine CHF. Progressive rapid ventricular pacing (38 days) resulted in impaired cardiovascular hemodynamics, increased atrial and left ventricular mass, decreased renal sodium excretion, and increased ET-1 plasma concentrations (all P < 0.05). Tissue analysis revealed significant increases in local ET-1 during CHF in left ventricular, renal, and pulmonary tissue, whereas a moderate increase in left atrial ET-1 did not reach statistical significance. In contrast, prepro-ET-1 gene expression was increased more than threefold in pulmonary tissue and more than twofold in left atrial myocardium with no increase in left ventricular or renal gene expression. The present studies demonstrate a differential pattern of ET-1 activation in cardiorenal and pulmonary tissue with a strong accumulation of ET-1 in kidney and lung during CHF. Although the observed increase in left ventricular and renal ET-1 in association with unaltered gene expression is consistent with increased uptake, pulmonary and atrial tissue may contribute to increased circulating and local ET-1 in CHF.
Ventricular remodeling during development and recovery from modified tachycardia-induced cardiomyopathy model
Yamamoto, Kazuhiro , Burnett, John C. , Meyer, Linda , Sinclair, L., Stevens, Tracy L., Redfield, Margaret M.

Mayo Clinic

American Journal of Physiology-Regulatory, Integrative and Comparative Physiology | December 24, 2017 | Volume: 271 | Issue: 6 | Pages: R1529-R1534

10.1152/ajpregu.1996.271.6.r1529 | PMID 8997349 Get It

his study was designed to characterize left ventricular (LV) function and mass in a modified cardiomyopathy model in the dog in which right ventricular pacing rates are gradually increased throughout 38 days. On the last day of the pacing protocol, ejection fraction was reduced (25 +/- 3 vs. 60 +/- 1%) and LV end-diastolic diameter index (a ratio of LV end-diastolic diameter to body weight, 2.09 +/- 0.02 vs. 1.79 +/- 0.08 mm/kg) and LV mass index (a ratio of LV mass to body weight, 5.2 +/- 0.3 vs. 4.3 +/- 0.2 g/kg) were greater than in the normal dogs (P < 0.05, respectively). Cardiac filling pressures increased, and LV diastolic function and coronary blood flow were impaired. After 4 wk of recovery from the progressive pacing protocol, LV end-diastolic diameter index (2.12 +/- 0.06 mm/kg) and LV mass index (5.6 +/- 0.2 g/kg) remained increased. Ejection fraction was improved (38 +/- 4%) but still depressed. LV diastolic function, coronary blood flow, and cardiac filling pressures returned to levels seen in the normal dogs. This modified cardiomyopathy model associated with LV hypertrophy complements the conventional tachycardia-induced cardiomyopathy model without LV hypertrophy.
Adrenomedullin in experimental congestive heart failure: cardiorenal activation
Jougasaki, Michihisa , Stevens, Tracy L., Borgeson, Daniel D., Luchner, Andreas, Redfield, Margaret M. , Burnett, John C.

Mayo Clinic

American Journal of Physiology-Regulatory, Integrative and Comparative Physiology | December 24, 2017 | Volume: 273 | Issue: 4 | Pages: R1392-R1399

10.1152/ajpregu.1997.273.4.r1392 | PMID 9362304 Get It

Adrenomedullin (ADM) is a new member of a family of vasodilating and natriuretic peptides that plays an important role in cardiorenal regulation. This study was designed to establish the plasma, urinary, cardiac, and renal tissue concentrations and immunohistochemical localizations of ADM in normal dogs and dogs with experimental congestive heart failure (CHF) produced by rapid ventricular pacing. Plasma ADM concentration was 5.6 ± 0.4 pg/ml in normal dogs and significantly increased to 14.5 ± 2.5 pg/ml in CHF dogs ( P < 0.05). Ventricular and renal tissue ADM were significantly increased in CHF dogs compared with normals. Immunohistochemical examination revealed positive ADM immunostaining within the myocytes, and ventricular ADM immunoreactivity was significantly more intense in CHF dogs than in normals. ADM immunoreactivity was also observed in the glomerulus, distal tubules, and medullary collecting duct cells in the kidney, and the intensities of ADM immunoreactivity in these sites were increased in CHF dogs compared with normals. In addition, ventricular ADM was a powerful marker for left ventricular mass, and circulating ADM correlated positively with left ventricular end-diastolic pressure and inversely with cardiac output and ejection fraction. Despite an increase in renal tissue ADM, urinary ADM did not increase in CHF dogs. The current study demonstrates that plasma concentration of ADM is increased in experimental CHF and that ventricular and renal ADM is activated in the progression of CHF. Tissue and circulating ADM also are markers for the alterations in myocardial structure and function. This study supports a potential role for ADM in the neurohumoral activation in experimental CHF.
Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure
Luchner, Andreas, Stevens, Tracy L., Borgeson, Daniel D., Redfield, Margaret M. , Wei, Chi-Ming, Porter, J G, Burnett, John C.

Mayo Clinic

American Journal of Physiology-Heart and Circulatory Physiology | December 22, 2017 | Volume: 274 | Issue: 5 | Pages: H1684-H1689

10.1152/ajpheart.1998.274.5.h1684 | PMID 9612380 Get It

Although brain natriuretic peptide (BNP) of myocardial origin is important in cardiovascular and renal function and as a marker of cardiac dysfunction, the expression of BNP in atrial and ventricular myocardium remains controversial both under normal conditions and in heart failure. We therefore determined left atrial and left ventricular (LV) gene expression and tissue concentration as well as circulating BNP during the evolution of rapid ventricular pacing-induced congestive heart failure (CHF) in the dog. Early LV dysfunction after 10 days of pacing was characterized by impaired LV function but maintained arterial pressure, and overt CHF after 38 days of pacing was characterized by further impaired LV function and decreased systemic arterial pressure. Under normal conditions, cardiac BNP mRNA and cardiac tissue BNP were of atrial origin. In early LV dysfunction, BNP mRNA and tissue BNP were markedly increased in the left atrium in association with an increase in circulating BNP but remained below or at the limit of detection in the LV. In overt CHF, BNP mRNA was further increased in the left atrium and first increased in the LV, together with an increase in LV tissue BNP and a further increase in circulating BNP. In the progression of CHF, early LV dysfunction is characterized by a selective increase in atrial BNP expression in association with increased circulating BNP. Overt CHF is characterized by an additional recruitment of ventricular BNP expression and a further increase in circulating BNP. These studies provide important new insight into the local and temporal regulation of cardiac BNP gene expression during the progression of heart failure and underscore the predominant endocrine role of atrial myocardium under normal conditions and in early LV dysfunction.
Impact of Excessive Weight Gain on Cardiovascular Outcomes in Type 1 Diabetes: Results From the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study
Purnell, Jonathan Q. , Braffett, Barbara H. , Zinman, Bernard, Gubitosi‐Klug, Rose , Sivitz, William, Bantle, John P., Ziegler, Georgia, Cleary, Patricia A., Brunzell, John D. , Nathan, D.M., Zinman, B., Crofford, O., Genuth, S., Brown-Friday, J., Crandall, J., Engel, S., Martinez, H., Phillips, M., Reid, M., Shamoon, H., Sheindlin, J., Gubitosi-Klug, R., Mayer, L., Pendegast, S., Zegarra, H., Miller, D., Singerman, L., Smith-Brewer, S., Novak, M., Quin, J., Genuth, Saul, Palmert, M., Brown, E., McConnell, J., Pugsley, P., Crawford, P., Dahms, W., Gregory, N.S., Lackaye, M.E., Kiss, S., Chan, R., Orlin, A., Rubin, M., Brillon, D., Reppucci, V., Lee, T., Heinemann, M., Chang, S., Levy, B., Jovanovic, L., Richardson, M., Bosco, B., Dwoskin, A., Hanna, R., Barron, S., Campbell, R., Bhan, A., Krüger, D., Jones, J.K., Edwards, P.A., Bhan, A., Carey, J.D., Angus, E., Thomas, A., Galprin, A., McLellan, M., Whitehouse, F., Bergenstal, R., Johnson, M., Gunyou, K., Thomas, L., Laechelt, J., Hollander, P., Spencer, M., Kendall, D., Cuddihy, R., Callahan, P., List, S., Gott, J., Rude, N., Olson, B., Franz, M., Castle, G., Birk, R., Nelson, J., Freking, D., Gill, L., Mestrezat, W., Etzwiler, D., Morgan, K., Aiello, L.P., Golden, E., Arrigg, P., Asuquo, V., Beaser, R., Bestourous, L., Cavallerano, J., Cavicchi, R., Ganda, O., Hamdy, O., Kirby, R., Murtha, T., Schlossman, D., Shah, S., Sharuk, G., Silver, P., Silver, P., Stockman, M., Sun, J., Weimann, E., Wolpert, H., Aiello, L. M., Jacobson, A., Rand, L., Rosenzwieg, J., Nathan, D.M., Larkin, M.E., Christofi, M., Folino, K., Godine, J., Lou, P., Stevens, C., Anderson, E., Bode, H., Brink, S., Cornish, C., Cros, D., Delahanty, L., deManbey, A., Haggan, C., Lynch, J., McKitrick, C., Norman, D., Moore, D., Ong, M., Taylor, C., Zimbler, D., Crowell, S., Fritz, S., Hansen, K., Gauthier‐Kelly, C., Service, F. J., Ziegler, G., Barkmeier, A., Schmidt, L., French, B., Woodwick, R., Rizza, R., Schwenk, W. F., Haymond, M., Pach, J., Mortenson, J., Zimmerman, B., Lucas, A., Colligan, R., Luttrell, L., Lopes-Virella, M., Caulder, S., Pittman, C., Patel, N., Lee, K., Nutaitis, M., Fernandes, J., Hermayer, K., Kwon, S., Blevins, A., Parker, J., Colwell, J., Lee, D., Soule, J., Lindsey, P., Bracey, M., Farr, A., Elsing, S., Thompson, T., Selby, J., Lyons, T., Yacoub-Wasef, S., Szpiech, M., Wood, D., Mayfield, R., Molitch, M., Adelman, D., Colson, S., Jampol, L., Lyon, A., Gill, M., Strugula, Z., Kaminski, L., MIRZA, R., Simjanoski, E., Ryan, D., Johnson, C., Wallia, A., Ajroud-Driss, S., Astelford, P., Leloudes, N., Degillio, A., Schaefer, B., Mudaliar, S., Lorenzi, G., Goldbaum, M., Jones, K., Prince, M., Swenson, M., Grant, I., Reed, R., Lyon, R., Kolterman, O., Giotta, M, Clark, T., Friedenberg, G., Sivitz, W.I., Vittetoe, B., Kramer, J., Bayless, M., Zeitler, R., Schrott, H., Olson, N., Snetselaar, L., Hoffman, R., MacIndoe, J., Weingeist, T., Fountain, C., Miller, R., Johnsonbaugh, S., Patronas, M., Carney, M., Mendley, S., Salemi, P., Liss, R., Hebdon, M., Counts, D., Donner, T., Gordon, J., Hemady, R., Kowarski, A., Ostrowski, D., Steidl, S., Jones, B., Herman, W.H., Martin, C.L., Pop-Busui, R., Greene, D. A., Stevens, M.J., Burkhart, N., Sandford, T, Floyd, J., Bantle, J., Flaherty, N., Terry, J., Koozekanani, D., Montezuma, S., Wimmergren, N., Rogness, B., Mech, M., Strand, T., Olson, J., McKenzie, L., Kwong, C., Goetz, F., Warhol, R., Hainsworth, D., Goldstein, D., Hitt, S., Giangiacomo, J., Schade, D.S., Canady, J.L., Burge, M. R., Das, A., Avery, R.B., Ketai, L.H., Chapin, J.E., Schluter, M.L, Rich, J., Johannes, C., Hornbeck, D., Schutta, M., Bourne, P.A., Brucker, A., Braunstein, S., Schwartz, S., Maschak-Carey, B. J., Baker, L., Orchard, T., Cimino, L., Songer, T., Doft, B., Olson, S., Becker, D., Rubinstein, D., Bergren, R.L., Fruit, J., Hyre, R., Palmer, C., Silvers, N., Lobes, L., Rath, P. Paczan, Conrad, P. W., Yalamanchi, S., Wesche, J., Bratkowksi, M., Arslanian, S., Rinkoff, J., Warnicki, J., Curtin, D., Steinberg, D., Vagstad, G., Harris, R., Steranchak, L., Arch, J., Kelly, K., Ostrosaka, P., Guiliani, M., Good, M., Williams, T., Olsen, K., Campbell, A., Shipe, C., Conwit, R., Finegold, D., Zaucha, M., Drash, A., Morrison, A., Malone, J.I., Bernal, M.L., Pavan, P. R., Grove, N., Tanaka, E.A., McMillan, D., Vaccaro‐Kish, J., Babbione, L., Solc, H., DeClue, T.J., Dagogo-Jack, S., Wigley, C., Ricks, H., Kitabchi, A., Chaum, E., Murphy, M.B., Moser, S., Meyer, D., Iannacone, A., Yoser, S., Bryer‐Ash, M., Schüßler, S., Lambeth, H., Raskin, P., Strowig, S., Basco, M., Cercone, S., Zinman, B., Barnie, A., Devenyi, R., Mandelcorn, M., Brent, M., Rogers, S., Gordon, A., Bakshi, N., Perkins, B., Tuason, L., Perdikaris, F., Ehrlich, R., Daneman, D., Perlman, K., Ferguson, S., Palmer, J., Fahlstrom, R., Boer, I.H.de, Kinyoun, J., Ottingham, L. Van, Catton, S., Ginsberg, J., McDonald, C., Harth, J., Driscoll, M., Sheidow, T., Mahon, J., Canny, C., Nicolle, D., Colby, P., Dupre, J., Hramiak, I., Rodger, NW, Jenner, M., Smith, T., Brown, W., May, M., Hagan, J. Lipps, Agarwal, A., Adkins, T., Lorenz, R., Feman, S., Survant, L., White, N. H., Levandoski, L., Grand, G., Thomas, M., Joseph, D., Blinder, K., Shah, G., Burgess, D., Boniuk, I., Santiago, J., Tamborlane, W., Gatcomb, P., Stoessel, K., Ramos, P., Fong, K., Ossorio, P., Ahern, J., Meadema-Mayer, L., Beck, C., Farrell, K., Quin, J., Gaston, P., Trail, R., Lachin, J., Backlund, J., Bebu, I., Braffett, B., Diminick, L., Gao, X., Hsu, W., Klumpp, K., Trapani, Victoria R., Trapani, V., Cleary, P., McGee, P., Sun, W. , Villavicencio, S., Anderson, K., Dews, L., Younes, Naji , Rutledge, B., Chan, K., Rosenberg, D. , Petty, B., Determan, A., Kenny, D., Williams, C., Cowie, C., Siebert, C., Steffes, M., Arends, V., Bucksa, J., Nowicki, M., Chavers, B., O’Leary, D., Polák, J. (Jaroslav), Harrington, A., Funk, L., Crow, R., Gloeb, B., Thomas, S., O’Donnell, C., Soliman, EZ, Zhang, Z.M., Li, Y., Campbell, C., Keasler, L., Hensley, S., Hu, J., Barr, M., Taylor, T., Prineas, R., Feldman, E.L., Albers, J.W., Low, P., Sommer, C., Nickander, K., Speigelberg, T., Pfiefer, M., Schumer, M., Moran, M., Farquhar, J., Ryan, C., Sandstrom, D., Geckle, M., Cupelli, E., Thoma, F., Burzuk, B., Woodfill, T., Danis, R., Blodi, B., Lawrence, D., Wabers, H., Gangaputra, S., Neill, S., Burger, M., Dingledine, J., Gama, V., Sussman, R., Davis, M., Hubbard, L., Budoff, M., Darabian, S., Rezaeian, P., Wong, N., Fox, M., Oudiz, R., Kim, L., Detrano, R., Cruickshanks, K., Bainbridg, K., Lima, J., Bluemke, D., Turkbey, E., Geest, R. J. van der, Liu, C., Malayeri, A., Jain, A., Miao, C., Chahal, H., Jarboe, R., Nathan, D.M., Monnier, V., Sell, D., Strauch, C., Hazen, S., Pratt, A., Tang, W., Brunzell, J., Purnell, J., Purnell, J., Natarajan, R., Miao, F., Zhang, L., Chen, Z., Paterson, A., Boright, A., Bull, S., Sun, L., Scherer, S., Lyons, T.J., Jenkins, A., Klein, R., Virella, G., Jaffa, A., Carter, R., Stoner, J., Garvey, W.T., Lackland, D., Brabham, M., McGee, D., Zheng, D., Mayfield, R. K., Maynard, J., Wessells, H., Sarma, A., Dunn, R., Holt, S., Hotaling, J., Kim, C., Clemens, Q., McVary, Kevin T. , Cuddihy, Robert , Paterson, Andrew D. , Gubitosi-Klug, Rose A , Paterson, Andrew , Zinman, Bernard , Sivitz, William I. , Ziegler, G., Nathan, D.M., Engel, Samuel S. , Reid, M., Genuth, Saul, McConnell, J., Campbell, R., Carey, J.D., Dd, Etzwiler, Cavallerano, Jerry D. , Larkin, M.E., DeManbey, Andrea, Ajroud-Driss, S., Mudaliar, S., Herman, W.H., Pop-Busui, R., Mech, Michael, Schade, D.S., Schwartz, S., Becker, Dj., Arch, J., Shipe, C., Drash, A L, Pavan, P R , DeClue, Terry J., Raskin, P., Rogers, S., Boer, I.H. de, Dupre, J, Tamborlane, W., Gatcomb, P., Bebu, I., Cleary, P., McGee, P., Steffes, M., Arends, V., Bm, Chavers, Polak, J., Feldman, E. L., Nickander, K. K., Pfiefer, M., Dittz, Dalton , Virella, Gabriel, Mayfield, R. K., Brown, Jonathan D. , Cuddihy, Robert M

Mayo Clinic

Diabetes Care | November 15, 2017 | Volume: 40 | Issue: 12 | Pages: 1756-1762

10.2337/dc16-2523 | PMID 29138273 Get It

OBJECTIVE Intensive treatment (INT) of type 1 diabetes reduces the incidence of cardiovascular disease (CVD) events compared with conventional treatment (CONV), but it also results in more weight gain. Our objective was to examine whether excessive weight gain from INT of type 1 diabetes is independently associated with subsequent CVD events. RESEARCH DESIGN AND METHODS Quartiles (Q) of weight gain in 1,213 participants aged 18 years and older at enrollment in the Diabetes Control and Complications Trial (DCCT) were determined within randomized treatment groups (INT vs. CONV) using change in BMI from baseline to the closeout DCCT visits. Effects of this weight gain on CVD risk factors and outcomes during an additional 20 years of observational follow-up were then determined. RESULTS The Q4 INT group experienced greater proportional weight gain (median change in BMI, 6.08 kg/m2), increases in CVD risk factors, and need for medications for hypertension and lipids compared with the Q1–3 INT and comparable CONV groups. Over a mean of 26 years of follow-up, the numbers of major and total CVD events were not statistically different in Q4 compared with Q1–3 of either the INT or CONV group. By year 14, however, the incident CVD event curve became significantly higher in the Q4 INT group than in the Q1–3 INT groups (P = 0.024) and was similar to that for the CONV group. CONCLUSIONS For the first 13 years after DCCT, INT for type 1 diabetes reduced macrovascular events compared with CONV, even when excessive weight gain occurred. After this, total CVD events significantly increased in the Q4 INT group, becoming equivalent to those in the CONV group. Longer follow-up is needed to determine whether this trend continues and results in more major CVD events.
Routes of Opioid Analgesic Therapy in the Management of Cancer Pain
Stevens, Rom A., Ghazi, Salim M.

Mayo Clinic

Cancer Control | August 30, 2017 | Volume: 7 | Issue: 2 | Pages: 132-141

10.1177/107327480000700203 | PMID 10783817 Get It

Optical transfer diagnosis differentiating benign and malignant pigmented lesions in a simulated primary care practice
Swanson, David C. , Venneuguès, Rowena Vicencio, Vicencio, S.Q., Garioch, J., Biryulina, M., Ryzhikov, G., Hamre, Børge , Zhao, Lu , Castellana, Frank S., Stamnes, Jakob J., Stamnes, Knut H.

Mayo Clinic

British Journal of Dermatology | August 18, 2017 | Volume: 178 | Issue: 2 | Pages: 541-546

10.1111/bjd.15898 | PMID 28832952 Get It

Regional left ventricular function does not predict survival in ischaemic cardiomyopathy after cardiac surgery
Prior, David , Stevens, Susanna R., Holly, Thomas A., Krejca, Michał , Paraforos, Alexandros, Pohost, Gerald M., Byrd, Krysti, Kukulski, Tomasz , Desvigne‐Nickens, Patrice , Amanullah, Aman, Lin, Grace , Al‐Khalidi, Hussein R. , Aldea, Gabriel S. , Bochenek, Andrzej , Berman, Daniel S. , Jones, Robert H. , Varadarajan, Padmini , Santambrogio, Carlo

Mayo Clinic

Heart | April 26, 2017 | Volume: 103 | Issue: 17 | Pages: 1359-1367

10.1136/heartjnl-2016-310693 | PMID 28446548 Get It

Objectives To define the prognostic contribution of global and regional left ventricular (LV) function measurements in patients with ischaemic cardiomyopathy randomised to coronary artery bypass graft surgery (CABG) with (n=501) or without (n=499) surgical ventricular reconstruction (SVR). Methods Novel multivariable methods to analyse global and regional LV systolic function were used to better formulate prediction models for long-term mortality following CABG with or without SVR in the entire cohort of 1000 randomised SVR hypothesis patients. Key clinical variables were included in the analysis. Regional function was classified according to the discreteness of anteroapical hypokinesia and akinesia into those most likely to benefit from SVR, those least likely and those felt to have intermediate likelihood of benefit from SVR. Results The most prognostic clinical variables identified in multivariable models include creatinine, LV end-systolic volume index (ESVI), age and NYHA (New York Heart Association) class. Addition of LV ejection fraction, LV end-diastolic volume index and regional function assessment did not contribute additional power to the model. Subgroup analysis based on regional function did not identify a cohort in which SVR improved mortality. Conclusions ESVI is the single parameter of LV function most predictive of mortality in patients with LV systolic dysfunction following CABG with or without SVR in multivariable models that include all key clinical and LV systolic function parameters. Assessment of regional cardiac function does not enhance prediction of mortality nor identify a subgroup for which SVR improves mortality. These results do not support elective addition of LV reconstruction surgery in patients undergoing CABG. Trial registration number NCT00023595.
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheum
Rider, Lisa G. , Ruperto, Nicolino , Bayat, Nastaran, Amato, Anthony A. , Dastmalchi, Maryam, Katz, James D. , Mammen, Andrew L. , Visser, Marianne de, Ytterberg, Steven R. , Lundberg, Ingrid E. , Chung, Lorinda, Dankó, Katalin , Torre, Ignacio García‐De La , Villa, Luca, Rinaldi, Mariangela, Rockette, Howard E., Lachenbruch, Peter A., Miller, Frederick W. , Vencovský, Jiří , Rouster‐Stevens, Kelly , Huber, Adam M. , Selva-O’Callaghan, Albert , Rutkove, Seward B. , Dimachkie, Mazen M. , Olesińska, Marzena , Chung, Leland W.K. , Shinjo, Samuel Katsuyuki , Ramchandren, Sindhu , Saketkoo, Lesley Ann , Mann, H. , Aggarwal, Rohit , Erman, Brian , Feldman, Brian Michael , Oddis, Chester V. , Chinoy, Hector , Cooper, Robert G. , Fiorentino, David Franklin , Isenberg, David , Visser, Marianne de, Chung, Lorinda, Song, Yeong Wook , Mann, Heřman , Vencovsky, Jiri , Shinjo, Samuel Katsuyuki , Selva O'Callaghan, Albert , Chung, Lorinda , García-De La Torre, Ignacio , Dimachkie, Mazen M , Lundberg, Ingrid E , Pistorio, Angela

Mayo Clinic

Arthritis & Rheumatology | April 6, 2017 | Volume: 69 | Issue: 5 | Pages: 898-910

10.1002/art.40064 | PMID 28382787 Get It

ObjectiveTo develop response criteria for adult dermatomyositis (DM) and polymyositis (PM).MethodsExpert surveys, logistic regression, and conjoint analysis were used to develop 287 definitions using core set measures. Myositis experts rated greater improvement among multiple pairwise scenarios in conjoint analysis surveys, where different levels of improvement in 2 core set measures were presented. The PAPRIKA (Potentially All Pairwise Rankings of All Possible Alternatives) method determined the relative weights of core set measures and conjoint analysis definitions. The performance characteristics of the definitions were evaluated on patient profiles using expert consensus (gold standard) and were validated using data from a clinical trial. The nominal group technique was used to reach consensus.ResultsConsensus was reached for a conjoint analysis–based continuous model using absolute percent change in core set measures (physician, patient, and extramuscular global activity, muscle strength, Health Assessment Questionnaire, and muscle enzyme levels). A total improvement score (range 0–100), determined by summing scores for each core set measure, was based on improvement in and relative weight of each core set measure. Thresholds for minimal, moderate, and major improvement were ≥20, ≥40, and ≥60 points in the total improvement score. The same criteria were chosen for juvenile DM, with different improvement thresholds. Sensitivity and specificity in DM/PM patient cohorts were 85% and 92%, 90% and 96%, and 92% and 98% for minimal, moderate, and major improvement, respectively. Definitions were validated in the clinical trial analysis for differentiating the physician rating of improvement (P < 0.001).ConclusionThe response criteria for adult DM/PM consisted of the conjoint analysis model based on absolute percent change in 6 core set measures, with thresholds for minimal, moderate, and major improvement.